FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000966098> ?p ?o ?g. }

• W2000966098 abstract "Patients with pathologic stage (p-Stage) IA non-small cell lung cancer (NSCLC) have a good survival rate because of possible curative resection. However, up to 10% of these patients relapse postoperatively. To identify unfavorable prognostic factors, we retrospectively analyzed the clinicopathological features of p-Stage IA disease, focusing on vascular invasion. Of 467 patients with p-Stage I NSCLC, 335 were diagnosed with p-Stage IA or IB disease based on a lesion size ≤3 cm and the presence of pleural invasion (PL). Univariate and multivariate analyses of recurrence-free survival (RFS) were performed with age, sex, PL, and vascular invasion (blood vessel invasion [v] and lymphatic vessel invasion [ly]) as variables. To examine vascular invasion, hematoxylin-eosin (HE), Elastica van Gieson staining, and immunostaining with anti-podoplanin antibody were performed. The presence or absence of v and ly was recorded; the number of involved vessels was counted. Survival rates were obtained using the Kaplan–Meier method and log-rank test. Multivariate analyses were performed using the Cox proportional hazards model. RFS differed significantly between patients with no or one involved blood vessel (0 v or 1 v) and those with ≥2 involved vessels (≥2 v). Similarly, RFS differed significantly between patients with no lymphatic vessel involvement (0 ly) and those with one involved lymphatic vessel (1 ly). Thus, BVI(+) and BVI(−) were defined as ≥2 v and 0 v + 1 v, and LVI(+) and LVI(−) as ≥1 ly and 0 ly, respectively. BVI and LVI together represented tumor vessel invasion (TVI). On multivariate analyses, PL and TVI were independently associated with recurrence. Additionally, patients with p-Stage IA TVI(+) disease had a comparable recurrence rate to those with p-Stage IB disease. Similar to PL, TVI is an important factor increasing the likelihood of recurrence. As HE staining alone is insufficient for evaluating vascular invasion, specific staining is necessary. Moreover, patients with p-Stage IA TVI(+) disease had a recurrence rate comparable to those with p-Stage IB disease; therefore, further studies should aim to elucidate whether patients with p-Stage IA TVI(+) disease should be administered postoperative chemotherapy similar to that received by p-Stage IB patients. The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/5213064891369688" @default.
• W2000966098 created "2016-06-24" @default.
• W2000966098 creator A5010618018 @default.
• W2000966098 creator A5018139084 @default.
• W2000966098 creator A5022455287 @default.
• W2000966098 creator A5030154468 @default.
• W2000966098 creator A5044085049 @default.
• W2000966098 creator A5045498137 @default.
• W2000966098 creator A5052453881 @default.
• W2000966098 creator A5071130428 @default.
• W2000966098 creator A5080015561 @default.
• W2000966098 date "2015-04-02" @default.
• W2000966098 modified "2023-09-30" @default.
• W2000966098 title "Prognostic impact of vascular invasion and standardization of its evaluation in stage I non-small cell lung cancer" @default.
• W2000966098 cites W1563790535 @default.
• W2000966098 cites W1973605344 @default.
• W2000966098 cites W1978665992 @default.
• W2000966098 cites W1981797385 @default.
• W2000966098 cites W1985833487 @default.
• W2000966098 cites W1985904501 @default.
• W2000966098 cites W1991760930 @default.
• W2000966098 cites W1997815910 @default.
• W2000966098 cites W1999854887 @default.
• W2000966098 cites W2009198963 @default.
• W2000966098 cites W2009898967 @default.
• W2000966098 cites W2026241624 @default.
• W2000966098 cites W2032154159 @default.
• W2000966098 cites W2033216418 @default.
• W2000966098 cites W2036012113 @default.
• W2000966098 cites W2044068080 @default.
• W2000966098 cites W2048022218 @default.
• W2000966098 cites W2050229398 @default.
• W2000966098 cites W2055503955 @default.
• W2000966098 cites W2075549113 @default.
• W2000966098 cites W2088482796 @default.
• W2000966098 cites W2097754170 @default.
• W2000966098 cites W2099040029 @default.
• W2000966098 cites W2110225392 @default.
• W2000966098 cites W2130963723 @default.
• W2000966098 cites W2136165793 @default.
• W2000966098 cites W2138368434 @default.
• W2000966098 doi "https://doi.org/10.1186/s13000-015-0249-5" @default.
• W2000966098 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4413537" @default.
• W2000966098 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25884820" @default.
• W2000966098 hasPublicationYear "2015" @default.
• W2000966098 type Work @default.
• W2000966098 sameAs 2000966098 @default.
• W2000966098 citedByCount "32" @default.
• W2000966098 countsByYear W20009660982015 @default.
• W2000966098 countsByYear W20009660982016 @default.
• W2000966098 countsByYear W20009660982017 @default.
• W2000966098 countsByYear W20009660982018 @default.
• W2000966098 countsByYear W20009660982019 @default.
• W2000966098 countsByYear W20009660982020 @default.
• W2000966098 countsByYear W20009660982021 @default.
• W2000966098 countsByYear W20009660982022 @default.
• W2000966098 countsByYear W20009660982023 @default.
• W2000966098 crossrefType "journal-article" @default.
• W2000966098 hasAuthorship W2000966098A5010618018 @default.
• W2000966098 hasAuthorship W2000966098A5018139084 @default.
• W2000966098 hasAuthorship W2000966098A5022455287 @default.
• W2000966098 hasAuthorship W2000966098A5030154468 @default.
• W2000966098 hasAuthorship W2000966098A5044085049 @default.
• W2000966098 hasAuthorship W2000966098A5045498137 @default.
• W2000966098 hasAuthorship W2000966098A5052453881 @default.
• W2000966098 hasAuthorship W2000966098A5071130428 @default.
• W2000966098 hasAuthorship W2000966098A5080015561 @default.
• W2000966098 hasBestOaLocation W20009660981 @default.
• W2000966098 hasConcept C10515644 @default.
• W2000966098 hasConcept C121608353 @default.
• W2000966098 hasConcept C125473707 @default.
• W2000966098 hasConcept C126322002 @default.
• W2000966098 hasConcept C142724271 @default.
• W2000966098 hasConcept C144301174 @default.
• W2000966098 hasConcept C146357865 @default.
• W2000966098 hasConcept C151730666 @default.
• W2000966098 hasConcept C181152851 @default.
• W2000966098 hasConcept C204232928 @default.
• W2000966098 hasConcept C2776256026 @default.
• W2000966098 hasConcept C2778740770 @default.
• W2000966098 hasConcept C2779013556 @default.
• W2000966098 hasConcept C2780965494 @default.
• W2000966098 hasConcept C38180746 @default.
• W2000966098 hasConcept C71924100 @default.
• W2000966098 hasConcept C86803240 @default.
• W2000966098 hasConceptScore W2000966098C10515644 @default.
• W2000966098 hasConceptScore W2000966098C121608353 @default.
• W2000966098 hasConceptScore W2000966098C125473707 @default.
• W2000966098 hasConceptScore W2000966098C126322002 @default.
• W2000966098 hasConceptScore W2000966098C142724271 @default.
• W2000966098 hasConceptScore W2000966098C144301174 @default.
• W2000966098 hasConceptScore W2000966098C146357865 @default.
• W2000966098 hasConceptScore W2000966098C151730666 @default.
• W2000966098 hasConceptScore W2000966098C181152851 @default.
• W2000966098 hasConceptScore W2000966098C204232928 @default.
• W2000966098 hasConceptScore W2000966098C2776256026 @default.
• W2000966098 hasConceptScore W2000966098C2778740770 @default.
• W2000966098 hasConceptScore W2000966098C2779013556 @default.
• W2000966098 hasConceptScore W2000966098C2780965494 @default.
• W2000966098 hasConceptScore W2000966098C38180746 @default.

• next